Abstract
Oral squamous cell carcinoma (OSCC) is an aggressive and heterogeneous tumor, with an overall survival rate that has remained stagnant at 50% over recent decades. Notably, even in advanced OSCC stages (III and IV), there can be both responsive and refractory patients, for whom there is no therapeutic option that promotes significant tumor remission in the majority of cases, especially wit…